Keto diet plus breast cancer drug shows promise in small study
NCT ID NCT03962647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether a 2-week very low-carbohydrate (ketogenic) diet combined with the drug letrozole is feasible and tolerable for people with early-stage estrogen receptor-positive (ER+) breast cancer. 31 postmenopausal women participated before surgery. The goal was to see if the diet could be followed and if it affected cancer cell growth and insulin signaling.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- New scan could predict hormone therapy success in breast cancer
- Egg-Freezing showdown: tamoxifen vs letrozole for breast cancer patients
- New drug combo shows promise against hereditary breast cancer
- Immune booster before chemo shows promise for tough breast cancer
- New hope for seniors: breast cancer combo shows promise in older patients